Loading…
Develops AAV gene therapies for inherited retinal diseases, neurodegenerative disorders and salivary gland disease.
Develops AAV gene therapies for inherited retinal diseases, neurodegenerative disorders and salivary gland disease.
Has no product on sale; income so far has come from partnership payments rather than sales, and trials are funded by those deals and investor money. It makes its own gene-therapy vectors at in-house plants rather than relying on contract manufacturers.
Moat: narrow (IP / patents, process know-how). Vertically integrated in-house AAV manufacturing platform across multiple gene therapy indications.
Headquarters: New York City, US · Founded: 2015 · Employees: 403
Size MeiraGTx (MGTX) is a United States Health Care company (Biotechnology) with a market value of $864M, the 2338th largest of 3,117 United States companies the cockpit tracks. Shares closed at $9.00 on 6 Nov 2026.
Performance Over six months the shares fell 8.3%, against -19.9% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue grew 948.4% over the last twelve months (peer median -1.8%); the operating margin is 45.9% (peer median -25.3%).
Valuation It trades at 2.1× enterprise value to sales against a peer median of 7.6× (2nd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +39%, so the hurdle is -49 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 68.2 points above its cost of capital (9.8% WACC).
Short interest Short interest is 6.7% of the free float (15 Oct 2026).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $398M | $81.4M | $33.3M | $14.0M | $15.9M |
| Revenue growth | — | +145% | +137% | -12% | — |
| Gross profit | $377M | $64.0M | -$3.34M | $287,000 | $7.20M |
| EBITDA | $195M | -$94.8M | -$151M | -$123M | -$108M |
| Net income | $79.0M | -$114M | -$148M | -$84.0M | -$130M |
| Free cash flow | $10.5M | -$50.2M | -$109M | -$126M | -$118M |
| Capital expenditure | $3.63M | $4.24M | $4.96M | $20.2M | $45.0M |
| Total debt | $112M | $88.7M | $84.8M | $89.3M | $92.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| MeiraGTx MGTX | $864M | -8% | +948% | 46% | 2.1× | -9.9% |
| 4D Molecular Therapeutics FDMT | $677M | +21% | +278,712% | -214% | 3.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MGTX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.3% | -5.6% | 7th lowest of 21 |
| 6-month return | -8.3% | -19.9% | 4th highest of 19 |
| Distance from 52-week high | -41.4% | -43.9% | 9th highest of 21 |
| Revenue growth (TTM) | +948.4% | -1.8% | highest of 17 |
| Operating margin | 45.9% | -25.3% | highest of 18 |
| EV / Sales | 2.1× | 7.6× | 2nd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -9.9% | 11.1% | 2nd least demanding of 8 |
| Growth delivered (Del g) | +39.2% | +4.4% | highest of 8 |
| Hurdle (Req g minus delivered) | -49.1 pp | +8.3 pp | least demanding of 8 |
| ROIC minus cost of capital | +68.2 pp | -15.2 pp | highest of 14 |
| EV / EBITDA | 4.3× | n/a | — |
| Net debt / EBITDA | -0.2× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | 2.1× | -9.9% | +39.2% |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 5.7× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | 3.5× | n/a | n/a |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 6.6× | n/a | n/a |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | 211.3× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | 4.3× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | 11.1× | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | 14,560.9× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $814M | -19% | -22% | 20% | 4.7× | 8.8% | +2.4% |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | 208.9× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | 26.5× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $803M | -12% | +21% | 11% | 3.9× | 20.1% | +11.8% |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $803M | +91% | -15% | -8% | 17.9× | 48.8% | +14.7% |
| Beijing SL Pharmaceutical 002038.SZ | China | $793M | -21% | -4% | -119% | 7.6× | -12.3% | -10.9% |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 1.4× | 6.6% | +4.4% |
| Alphamab Oncology 9966.HK | Hong Kong | $777M | -39% | -32% | -38% | 8.2× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 4.7× | 11.1% | +2.3% |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | 13.1× | 43.2% | +21.5% |